The Medicines and Healthcare products Regulatory Agency (MHRA)’s makes the UK the first country in the world who approve Molnupiravir for the treatment of COVID-19. It is branded as Lagevrio in the UK and has been in the global spotlight for the treatment of Covid-19, as it showed promising results so far. It is the world’s first approved antiviral drug for the treatment of COVID-19 that can be taken by mouth rather than administered intravenously. It means it can be administered outside of a hospital setting, before the progression of Covid-19 to a severe stage. Clinical trials showed that molnupiravir show promising results only when administered at the early stages of infection. The MHRA has recommended that individuals should start treatment with molnupiravir as soon as they came to know that they are COVID-19 positive i.e., within the five days of the onset of symptoms.